Please login to the form below

Not currently logged in
Email:
Password:

GSK completes acquisition of Steifel

GSK has acquired the total share capital of Steifel Laboratories Inc in a cash deal worth $2.9bn

GlaxoSmithKline (GSK) has acquired the total share capital of Steifel Laboratories Inc in a cash deal worth $2.9bn.

As part of the deal, GSK has assumed $400m of net debt and may, dependent on the future performance of the business, be obliged to make additional cash payments of up to $300m.

GSK will operate its new dermatology business unit under the name Steifel, a GSK company.

Charles Stiefel, chairman of Stiefel, said: "As part of GSK, we are stronger, more competitive and continue to be a driving force in dermatology around the world. We are excited to combine GSK's prescription dermatology products, such as Bactroban, Cutivate and Altabax, with Stiefel's portfolio, including brands such as Duac, Olux E and Soriatane."

In 2008, Steifel products made approximately $900m in sales. This, combined with GSK's 2008 prescription dermatology product sales of $550m, creates pro forma revenues of around $1.5m – an 8 per cent share of the global prescription dermatology market.

22nd July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics